Monday, March 03, 2025 | 02:03 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Review panel asks vaccine makers to submit more data to get authorisation

Experts ask Bharat Biotech for phase 3 data, Serum's UK approval status

Coronavirus, vaccine, covid, drugs, clinical trials
Premium

The decision of the expert committee would be considered final as the DCGI is unlikely to take a contrarian call, according to sources.

Sohini Das Mumbai
The wait for the Covid-19 vaccine just got a bit longer for India as two key players were told on Wednesday that their clinical trial data was inadequate for a fast-track approval. At a virtual review meeting, spread through the day, the subject expert committee (SEC) asked vaccine makers Bharat Biotech International (BBIL) and Serum Institute of India (SII) to come back with more data for getting an accelerated marketing authorisation.      

The expert committee, which is advising the Drug Controller General of India (DCGI) on the matter, flagged several concerns such as why the AstraZeneca vaccine, with which

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in